| Dr Justin Neil Mccray, MD | |
|
1 Mellon Way, Latrobe, PA 15650-1197 | |
| (724) 537-1000 | |
| Not Available |
| Full Name | Dr Justin Neil Mccray |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 17 Years |
| Location | 1 Mellon Way, Latrobe, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992968531 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Excela Health Home Care & Hospice | Greensburg, PA | Hospice |
| Excela Health Latrobe Hospital | Latrobe, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Excela Health Physician Practices, Inc | 6204737117 | 438 |
News Archive
After every meal, the body must prevent the immune system from launching an all-out fight against food.
Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, showed increased benefit among women sharing certain traits.
Talimogene laherparepvec has been approved since December 2015 for adults with advanced melanoma.
Research has shown the efficacy of a pharmaceutical drug known as sunitinib which halts progress of metastatic kidney cancer.
› Verified 3 days ago
| Entity Name | Excela Health Physician Practices, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821225202 PECOS PAC ID: 6204737117 Enrollment ID: O20040322001393 |
News Archive
After every meal, the body must prevent the immune system from launching an all-out fight against food.
Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, showed increased benefit among women sharing certain traits.
Talimogene laherparepvec has been approved since December 2015 for adults with advanced melanoma.
Research has shown the efficacy of a pharmaceutical drug known as sunitinib which halts progress of metastatic kidney cancer.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Justin Neil Mccray, MD 528 N Maple Ave, Greensburg, PA 15601-1838 Ph: (440) 724-6592 | Dr Justin Neil Mccray, MD 1 Mellon Way, Latrobe, PA 15650-1197 Ph: (724) 537-1000 |
News Archive
After every meal, the body must prevent the immune system from launching an all-out fight against food.
Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, showed increased benefit among women sharing certain traits.
Talimogene laherparepvec has been approved since December 2015 for adults with advanced melanoma.
Research has shown the efficacy of a pharmaceutical drug known as sunitinib which halts progress of metastatic kidney cancer.
› Verified 3 days ago
David Garzarelli, Hospitalist Medicare: Medicare Enrolled Practice Location: 1 Mellon Way, Upmc St Margaret Hospital, Latrobe, PA 15650 Phone: 724-537-1801 | |
Dr. Samuel Anthony Valletta, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1 Mellon Way, Latrobe, PA 15650 Phone: 724-537-1207 | |
Dr. Christopher Moore, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1 Mellon Way, Latrobe, PA 15650 Phone: 724-537-1801 |